Recombinant Human Protein JTB (JTB)

What is the basic structure of human JTB protein?

Human JTB protein is a 146 amino acid polypeptide with a molecular weight of approximately 16.4 kDa. The protein consists of a 30-amino acid signal sequence that can be processed and removed, a 75-amino acid cysteine-rich extracellular domain, a 21-amino acid hydrophobic transmembrane domain, and a 20-amino acid intracellular/cytoplasmic domain. The three main domains together account for about 13.2 kDa of the total molecular mass . Recombinant versions typically include tags such as His-tags for purification purposes, as seen in the sequence: MGSSHHHHHH SSGLVPRGSH MGSEAPVQEE KLSASTSNLP CWLVEEFVVA EECSPCSNFR AKTTPECGPT GYVEKITCSS SKRNEFKSCR SALMEQRL .

Where is JTB protein typically localized in cells?

JTB exhibits dynamic localization within cells. It can be found in the cell membrane, mitochondria, and microtubule cytoskeleton . During mitosis, JTB demonstrates specific localization patterns, appearing in the centrosome, spindle, and cytoplasm at different stages of cell division . This dynamic localization suggests its involvement in multiple cellular processes, particularly those related to cell division and mitotic regulation.

What are the primary biological functions of JTB protein?

JTB protein is required for normal cytokinesis during mitosis and plays an important role in regulating cell proliferation . It may function as a component of the chromosomal passenger complex (CPC), which acts as a key regulator of mitosis with essential functions at the centromere in ensuring correct chromosome alignment and segregation . JTB increases AURKB (Aurora Kinase B) activity and is required for chromatin-induced microtubule stabilization and spindle assembly . Additionally, it inhibits apoptosis induced by TGFB1 (Transforming Growth Factor Beta 1) .

What expression systems are typically used for recombinant JTB production?

Recombinant Human JTB protein is commonly expressed in Escherichia coli bacterial expression systems . This system allows for high-yield production of the protein fragment (typically amino acids 31-105) with greater than 85% purity as determined by SDS-PAGE . For research applications, the recombinant protein is often produced with affinity tags such as poly-histidine (His) tags to facilitate purification and detection .

What buffer conditions are optimal for JTB protein stability?

Based on commercial recombinant JTB preparations, the protein exhibits stability in buffer systems containing 20mM Tris-HCl (pH 8.0), 0.15M NaCl, 10% glycerol, and 1mM DTT . The protein is typically maintained at a concentration of approximately 0.25 mg/ml in this buffer system . When designing experiments involving JTB protein, it is advisable to avoid significant deviations from these buffer conditions unless specific compatibility testing has been performed.

What techniques are effective for studying JTB protein interactions?

Immunoprecipitation (IP) followed by mass spectrometry is an effective approach for identifying JTB protein interaction partners . In research settings, epitope-tagged versions of JTB (using HA, His, or FLAG tags) can be expressed in relevant cell lines to facilitate pulldown experiments . For protein-protein interaction studies, transient and stable transfection of target cells (such as MCF7 breast cancer cells) with tagged JTB constructs, followed by extraction, purification, and analysis using techniques like nano-liquid chromatography tandem mass spectrometry (nanoLC-MS/MS) has proven effective .

How is JTB implicated in cancer development?

The human JTB gene is located on chromosome 1 at position q21, a region involved in unbalanced translocation in various types of cancer . JTB protein is ubiquitously present in normal cells but is found to be overexpressed in several cancer types, particularly prostate and breast cancer . Research indicates that JTB can function as either a tumor suppressor or an oncogene depending on the specific malignancy context . This dual functionality makes it an intriguing target for cancer research, as understanding its context-dependent behavior may provide insights into cancer development mechanisms.

What methodologies are used to study JTB's role in breast cancer?

Researchers investigating JTB's role in breast cancer typically employ transfection of breast cancer cell lines (such as MCF7) with sense orientation of hJTB cDNA in expression vectors containing epitope tags (HA, His, and FLAG) . Both transient and stable transfection approaches have been utilized, with protein expression confirmed via Western blotting . Proteome analysis using techniques such as SDS-PAGE separation followed by in-gel digestion and nanoLC-MS/MS has been instrumental in identifying dysregulated proteins in JTB-overexpressing cells . Gene Set Enrichment Analysis (GSEA) algorithms are then applied to investigate biological processes and pathways associated with JTB protein upregulation .

What pathways are affected by JTB overexpression in cancer cells?

Gene Set Enrichment Analysis in JTB-overexpressing breast cancer cells has identified four significantly enriched gene sets from upregulated pathways: mitotic spindle assembly, estrogen response late, epithelial-to-mesenchymal transition (EMT), and estrogen response early . Overexpression of JTB is significantly associated with increased expression of proteins related to cytoskeletal organization and biogenesis, mitotic spindle organization, extracellular matrix remodeling, cellular response to estrogen, proliferation, migration, metastasis, lipid biogenesis, endocrine therapy resistance, and antiapoptosis . Additional affected pathways include tumor microenvironment acidification, transmembrane transport, glycolytic flux, iron metabolism, oxidative stress, metabolic reprogramming, and cancer drug resistance .

How can proteomics approaches be optimized for JTB functional studies?

For advanced JTB functional studies using proteomics, researchers should consider a comparative proteome analysis approach. This methodology involves transfecting cells with JTB-expressing constructs alongside appropriate controls, followed by protein extraction, separation, and analysis . Specifically, proteins should be extracted from transfected cells, separated using SDS-PAGE, subjected to in-gel digestion, and analyzed using high-resolution mass spectrometry such as nano-Acquity UPLC coupled with QTOF Xevo G2 Mass Spectrometer . Data processing can be optimized using specialized software such as Mascot 2.4 server and Scaffold 4.1 software . To enhance the functional assessment, Gene Set Enrichment Analysis should be performed using standardized algorithms (such as those available at https://www.gsea-msigdb.org/) with appropriate parameters: Hallmark enrichment with 1000 permutations, maximum size of 500 to exclude larger sets, and minimum size of 3 to exclude smaller sets .

What are the considerations for designing JTB overexpression and knockdown experiments?

When designing JTB manipulation experiments, researchers should consider several critical factors. For overexpression studies, the sense orientation of hJTB cDNA should be cloned into expression vectors containing epitope tags (HA, His, FLAG) under a strong promoter such as CMV . For knockdown studies, shRNA plasmids targeting JTB have proven effective . Both transient and stable transfection approaches should be evaluated based on the specific research question, with transient systems offering quicker results but stable systems providing more consistent expression levels for long-term studies. Expression levels must be rigorously confirmed via Western blotting using appropriate antibodies . When assessing biological effects, researchers should examine multiple cellular processes including proliferation, mitotic spindle organization, apoptosis resistance, and mitochondrial function, as JTB has been implicated in all these processes .

How can JTB be evaluated as a potential biomarker for cancer?

To evaluate JTB as a cancer biomarker, researchers should employ a multi-dimensional approach. First, quantitative expression analysis should be performed across diverse cancer types and matched normal tissues using techniques such as qRT-PCR, Western blotting, and immunohistochemistry. Since JTB is ubiquitously present in normal cells but overexpressed in various cancer types including prostate and breast cancer , establishing definitive expression thresholds is critical. Second, correlation analyses between JTB expression levels and clinical parameters (stage, grade, survival) should be conducted using patient cohorts with comprehensive clinical data. Third, multivariate analyses incorporating JTB with established biomarkers should be performed to assess its independent prognostic value. Finally, functional studies examining the effects of JTB modulation on cancer-related phenotypes (as described in studies using MCF7 breast cancer cells ) are essential to establish biological relevance. The protein's association with pathways like mitotic spindle assembly, estrogen response, and epithelial-to-mesenchymal transition makes it particularly relevant for breast cancer biomarker development .

What are common challenges in purifying recombinant JTB protein?

Purification of recombinant JTB protein presents several challenges researchers should anticipate. First, while E. coli expression systems yield high protein quantities, they lack post-translational modifications that may be present in naturally occurring JTB . Second, the protein contains multiple cysteine residues in its extracellular domain , which can form incorrect disulfide bonds during recombinant expression, potentially affecting protein folding and function. To address these challenges, researchers should consider including reducing agents like DTT (1mM) in purification buffers , optimizing expression conditions (temperature, induction time), and employing affinity chromatography methods leveraging the His-tag commonly incorporated in recombinant constructs . Additionally, testing the biological activity of purified protein is recommended prior to use in cell culture experiments .

How can the biological activity of recombinant JTB be verified?

Verifying the biological activity of recombinant JTB requires multiple complementary approaches. First, structural integrity should be confirmed via techniques such as circular dichroism or limited proteolysis. Second, functional assays should target known JTB activities, including: (1) effects on cell division and cytokinesis in relevant cell lines; (2) modulation of AURKB activity through in vitro kinase assays; (3) assessment of mitochondrial membrane potential in cells treated with recombinant JTB, as overexpression has been shown to reduce mitochondrial membrane potential ; and (4) evaluation of effects on TGFB1-induced apoptosis pathways . For advanced validation, researchers could perform rescue experiments in JTB-knockdown cells to determine if the recombinant protein can restore normal cellular functions disrupted by endogenous JTB depletion.

What statistical approaches are recommended for analyzing JTB-related proteomics data?

For robust analysis of JTB-related proteomics data, a structured statistical approach is essential. As demonstrated in published research, data should be presented as mean ± S.E.M. with statistical comparisons made using paired Student's t-test where appropriate . P values <0.05 should be considered statistically significant . For pathway enrichment analyses, Gene Set Enrichment Analysis (GSEA) with appropriate thresholds is recommended, with a false discovery rate (FDR) of <0.25 (25%) considered statistically significant according to GSEA standards . When analyzing dysregulated proteins, both upregulated and downregulated proteins should be systematically categorized by biological function to provide a comprehensive understanding of JTB's impact on cellular processes. Multivariate analyses may also be applied to identify potential confounding factors and ensure the observed changes are specifically attributable to JTB manipulation.

How should contradictory findings about JTB's role as oncogene versus tumor suppressor be reconciled?

The apparent contradiction regarding JTB's role as either an oncogene or tumor suppressor across different malignancies requires careful analytical approaches for reconciliation. Researchers should consider: (1) Tissue-specific context - systematically comparing JTB's molecular interactions and downstream effectors across different tissue types using techniques like comparative proteomics and transcriptomics; (2) Genetic background - evaluating how the broader mutational landscape of different cancers might modify JTB's functionality; (3) Signaling pathway integration - mapping how JTB interfaces with established oncogenic and tumor-suppressive pathways in each cancer type; and (4) Protein isoforms or post-translational modifications - investigating whether different JTB variants predominate in different contexts. Additionally, dose-dependent effects should be considered, as the concentration of JTB may determine whether it promotes or suppresses cancer-related phenotypes, similar to other proteins with context-dependent functions in cancer biology.